Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Positive and Negative Syndrome Scale (PANSS) is a widely used instrument for assessing symptom severity in schizophrenia, whereas the Personal and Social Performance Scale (PSP) provides a practical measure of functional outcomes. This study aimed to evaluate the predictive validity of the PSP for PANSS outcomes in individuals with schizophrenia.
A total of 763 patients diagnosed with schizophrenia and receiving paliperidone treatment were recruited in a 12-week multicenter prospective study. Among participants with a baseline PANSS score greater than 90, those with a 12-week PSP score above 60 were more likely to achieve a reduction of more than 20% in PANSS scores, whereas those with a PSP score below 60 showed less improvement.
This study employed a 12-week, multicenter, prospective research design focusing on the administration of the antipsychotic medication paliperidone. Assessments were conducted at baseline, week 4, and week 12. Two widely used scales-the PANSS and PSP-were utilized to evaluate patients before and after treatment, followed by a correlation analysis of the results.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The Effects of paliperidone on symptom improvement in schizophrenia | Experimental | Patients diagnosed with schizophrenia and receiving paliperidone treatment were recruited in a 12-week multicenter prospective study. Among participants with a baseline PANSS score greater than 90, those with a 12-week PSP score above 60 were more likely to achieve a reduction of more than 20% in PANSS scores, whereas those with a PSP score below 60 showed less improvement. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| This study employed a 12-week, multicenter, prospective research design focusing on the administration of the antipsychotic medication paliperidone. | Drug | Assessments were conducted at baseline, week 4, and week 12. Two widely used scales-the PANSS and PSP-were utilized to evaluate patients before and after treatment, followed by a correlation analysis of the results. |
| Measure | Description | Time Frame |
|---|---|---|
| the gender different in the effect of paliperidone treatment in schizophrenia | The difference of paliperidone treatment between males and females were explored at baseline, week 4, and week 12. | The differences were evaluated before treatment, and week 4 and week 12 after treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| The PANSS responses in schizophrenia with paliperidone | The Positive and Negative Syndrome Scale (PANSS) was utilized to evaluate the symptom improvment in individuals undergoing antipsychotic treatment. PANSS scores below 58 indicatemild symptoms, higher scores indicate more severe symptoms. | The responses of PANSS were evaluated before the treatment, and week 4 and week 12 after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| The predictive validity of the PSP for PANSS outcomes in schizophrenia | To explore the Personal and Social Performance Scale (PSP) as a practical and efficient tool for monitoring treatment response and functional outcomes in schizophrenia, or not. The scores of PSP with higher scores indicate higher functional recovery. | PSP was utilized to evaluate patients before treatment, and week 4 and week 12 after treatment. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Calo Psychiatric Center | Pingtung City | 925 | Taiwan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Result | References 1. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005; 17: 113-135. 2. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry. 2008; 21: 630-639. 3. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276. 4. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988; 23: 99-110. 5. Lim K, Peh OH, Yang Z, Rekhi G, Rapisarda A, See YM, Rashid NAA, Ang MS, Lee SA, Sim K, Huang H, Lencz T, Lee J, Lam M. Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. Asian J Psychiatry. 2021; 62: 102732. 6. Jelastopulu E, Giourou E, Merekoulias G, Mestousi A, Moratis E, Alexopoulos EC. Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Sydrome Scale (PANSS) in a Greek sample of patients with schizophrenia. BMC Psychiatry. 2014; 14: 197. 7. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000; 101: 323-329. 8. Lung FW, Shu BC, Kao WT, Chen CN, Ku YC, Tzeng DS. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. BMC Med Genet. 2009; 10: 147. 9. Tzeng DS, Lian LC, Chang CU, Yang CY, Lee GT, Pan P, Lung FW. Healthcare in schizophrenia: effectiveness and progress of a redesigned care network. BMC Health Serv Res. 2007; 7: 129. 10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Assoc | ||
| 41864953 |
Not provided
Not provided
patient privacy
Not provided
Not provided
Not provided
Not provided
Not provided
This study employed a 12-week, multicenter, prospective research design focusing on the administration of the antipsychotic medication paliperidone. Assessments were conducted at baseline, week 4, and week 12. Two widely used scales-the PANSS and PSP-were utilized to evaluate patients before and after treatment, followed by a correlation analysis of the results.
Not provided
Not provided
Not provided
Not provided
|
| Derived |
| Cheng KD, Lung FW. Predictive validity of the personal and social performance scale for PANSS outcomes in schizophrenia: a severity-stratified study. BMC Res Notes. 2026 Mar 21;19(1):197. doi: 10.1186/s13104-026-07773-y. |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided